# Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

> clinical trial · VERIFIED · 2026-08-18

Status: RECRUITING · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Condition: HER2-negative Breast Cancer

- Company: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06993506

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.